Prospective Administration of Anti-NGF Treatment Effectively Suppresses Functional Connectivity Alterations Following Cancer-Induced Bone Pain in Mice by Buehlmann, David et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Prospective Administration of Anti-NGF Treatment Effectively Suppresses
Functional Connectivity Alterations Following Cancer-Induced Bone Pain in
Mice
Buehlmann, David ; Ielacqua, Giovanna Diletta ; Xandry, Jael ; Rudin, Markus
Abstract: Cancer-induced bone pain is abundant among advanced stage cancer patients and arises from a
primary tumor in the bone or skeletal metastasis of common cancer types such as breast, lung or prostate
cancer. Recently, antibodies targeting nerve growth factor (NGF) have been shown to effectively relieve
neuropathic and inflammatory pain states in mice and in humans. While efficacy has been shown in mice
on a behavioral level, effectiveness in preventing pain-induced functional rearrangements in the central
nervous system has not been shown. Therefore we assessed longitudinal whole-brain functional connec-
tivity using resting-state fMRI in a mouse model of cancer-induced bone pain. We found functional
connectivity between major hubs of ascending and descending pain pathways such as the periaqueduc-
tal gray, amygdala, thalamus as well as cortical somatosensory regions to be affected by a developing
cancer pain state. These changes could be successfully prevented through prospective administration
of a monoclonal anti-NGF antibody (mAb911). This indicates efficacy of anti-NGF treatment to pre-
vent pain-induced adaptations in brain functional networks following persistent nociceptive input from
cancer-induced bone pain. Additionally, it highlights the suitability of resting-state fMRI readouts as an
indicator of treatment response on the basis of longitudinal functional network changes.
DOI: https://doi.org/10.1097/j.pain.0000000000001388
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-153741
Journal Article
Accepted Version
Originally published at:
Buehlmann, David; Ielacqua, Giovanna Diletta; Xandry, Jael; Rudin, Markus (2019). Prospective Admin-
istration of Anti-NGF Treatment Effectively Suppresses Functional Connectivity Alterations Following
Cancer-Induced Bone Pain in Mice. Pain, 160(1):151-159.
DOI: https://doi.org/10.1097/j.pain.0000000000001388
PAIN Publish Ahead of Print
DOI: 10.1097/j.pain.0000000000001388
 
 
 
Prospective Administration of Anti-NGF Treatment Effectively Suppresses 
Functional Connectivity Alterations Following Cancer-Induced Bone Pain in 
Mice 
David Buehlmann1,2, Giovanna Diletta Ielacqua1, Jael Xandry3, Markus Rudin1,2,3,* 
1 Institute for Biomedical Engineering, ETH & University of Zurich, Zurich, Switzerland 
2 Neuroscience Center Zurich, ETH & University of Zurich, Zurich, Switzerland 
3 Institute of Pharmacology & Toxicology, University of Zurich, Zurich, Switzerland 
 
 
* Corresponding author:   
Markus Rudin 
Institute for Biomedical Engineering 
ETH & University of Zurich 
Wolfgang-Pauli-Str. 27 
CH-8093 Zurich 
rudin@biomed.ee.ethz.ch 
 AC
CE
PT
ED
Copyright  8 8 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.            201
1 
 
Abstract 
Cancer-induced bone pain is abundant among advanced stage cancer patients and arises from a 
primary tumor in the bone or skeletal metastasis of common cancer types such as breast, lung or 
prostate cancer. Recently, antibodies targeting nerve growth factor (NGF) have been shown to 
effectively relieve neuropathic and inflammatory pain states in mice and in humans. While 
efficacy has been shown in mice on a behavioral level, effectiveness in preventing pain-induced 
functional rearrangements in the central nervous system has not been shown. Therefore we 
assessed longitudinal whole-brain functional connectivity using resting-state fMRI in a mouse 
model of cancer-induced bone pain. We found functional connectivity between major hubs of 
ascending and descending pain pathways such as the periaqueductal gray, amygdala, thalamus 
as well as cortical somatosensory regions to be affected by a developing cancer pain state. 
These changes could be successfully prevented through prospective administration of a 
monoclonal anti-NGF antibody (mAb911). This indicates efficacy of anti-NGF treatment to prevent 
pain-induced adaptations in brain functional networks following persistent nociceptive input from 
cancer-induced bone pain. Additionally, it highlights the suitability of resting-state fMRI readouts 
as an indicator of treatment response on the basis of longitudinal functional network changes.  
 
Keywords: resting-state fMRI; Chronic Pain; metastatic bone cancer; Nerve growth factor; 
pharmacological modulation 
1. Introduction 
Common cancer types like breast, lung and prostate cancer have a high predisposition of 
forming skeletal metastasis in bones like femur, tibia, ribs and vertebrae [11]. Tumor formation in 
bones frequently leads to anemia, increased risk of fracture, susceptibility to infections and in 
many cases to a severe pain state, impairing patient’s quality of life. Cancer-induced bone pain is 
a complex pain state known to cause persistent pain, movement evoked pain and severe 
episodes of breakthrough pain, which are particularly difficult to manage [30]. Commonly, ongoing 
cancer pain is managed adhering to the World Health Organization’s analgesic ladder in 
combination with adjuvant therapies such as bisphosphonates, non-steroidal anti-inflammatory 
drugs, opioids, radiotherapy or surgical interventions [51]. While these therapies often exert 
severe side-effects especially upon long-term use, they also fail to address spontaneous 
breakthrough pain. Therefore effective treatment of cancer-induced bone pain is still not 
available.   
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In order to better understand mechanisms involved, a preclinical model of bone cancer pain 
has been developed by orthotopic implantation of tumor cells [12,24]. The model was shown to 
reproduce clinical symptoms of cancer-induced bone pain including spontaneous and evoked 
pain, correlating with tumor growth and cancer-induced bone remodeling [30]. Besides osteoclast 
mediated bone resorption, tumor acidosis and mediators released by tumor-associated stromal 
cells, tumor-induced damage to peripheral nociceptors was found to be a major contributor of 
cancer pain [40,46]. Nociceptive Aδ- and C-fibers innervating the adult bone are to the largest 
extent tyrosine kinase A (TrkA) positive, target receptor of the nerve growth factor (NGF) [31]. 
NGF sequestering antibodies for treating cancer pain were found to be highly effective in 
reducing tumor-induced nerve sprouting, neuroma formation and bone cancer pain in mice 
[29,47]. Effective relieve from skeletal pain was further indicated in clinical studies in different 
disease states like osteoarthritis and chronic lower back pain [9].   
Along with these peripheral effects, cancer-induced bone pain show very distinct 
neurochemical alterations in the central nervous system (CNS) at the level of the spinal cord such 
as overexpression of dynorphin and c-FOS, as well as actrocyte hypertrophy [25]. These effects 
could partly be prevented through application of anti-NGF treatment [47]. While anti-NGF 
treatment efficacy is largely described assessing peripheral, behavioral or spinal cord level 
readouts, its effects on the brain remain unknown. As the conscious experience of pain is 
ultimately generated in the brain, assessing peripheral effects of anti-NGF treatment on the brain 
in a cancer pain state might give further insights into how effective pain relieve is.  
Therefore, we assessed whole brain functional connectivity (FC) using resting-state functional 
magnetic resonance imaging (rs-fMRI) in a mouse model of bone cancer pain. Rs-fMRI infers FC 
based on the synchronicity of spontaneous activity across brain regions [4,5,13,32] and poses a 
unique window for assessing the functional state of the brain and how it is affected upon a 
disease state [16,18,50]. By assessing longitudinal FC, we evaluated efficacy of the anti-NGF 
antibody mAb911 to modulate changes in brain networks following a cancer-induced bone pain 
state in mice.   
 
2. Material and Methods 
Animals & Experimental Design 
Animal experiments were conducted in accordance with regulations of the Cantonal Veterinary 
Office in Zürich, Switzerland. Female C57BL/6 mice at 8-10 weeks of age were obtained from 
Janvier Labs (Laval, France). Mice were held in individually ventilated cages in a 12/12h 
alternating light/dark cycle at 22-24°C with unrestricted access to food and water, experiments 
were conducted during light cycle. They were allocated to groups, and groups were allocated to 
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cages in a randomized fashion using R’s sample function [42]. Separation of groups by cages 
was decided to prevent social transfer of pain which has been previously described [48]. Female 
mice were chosen due to the higher prevalence of females to develop a chronic pain state [22]. 
fMRI experiments were carried out at baseline (BL) before tumor inoculation (0d.p.i.), 10 and 
20 days post injection (d.p.i.) of the tumor cells. Anti-NGF treatment and behavioral readouts of 
pain were carried out in parallel. Treatment and behavioral readouts were initiated 1 week post 
tumor inoculation (8d.p.i.). Thereby, anti-NGF treatment was injected after completion of 
behavioral experiments. Experimental groups used in this study and their characteristics are 
indicated in Table 1. An outline of the experimental design is indicated in Figure 1.  
Mouse Model of Bone Metastasis 
The mouse model of chronic pain from bone metastasis was adopted form previous published 
procedures and refined for our purposes [23,26]. In short, EO771 breast cancer cells were 
cultured to 80% confluency in RPMI medium supplemented with 10% fetal bovine serum at 37°C. 
Mice of the tumor-bearing groups (Tumor+Vehicle and Tumor+anti-NGF) were injected with 105 
cells in 10µl in the medulla of the right tibia while mice of the control-groups (Sham+Vehicle and 
Sham+anti-NGF) were injected with 10µl PBS instead. Therefore, mice were anesthetized at 3% 
isofluorane in a 1:5 mixture of O2/air, the hair was removed and skin disinfected on the injected 
leg. To access the medullary space, a hole was drilled through the tibial plateau using a 27-G 
needle. Proper location of the needle was verified in two planar x-ray radiographs (35kW/10s, 4x 
geometric magnification) of a 90° angle using a Faxitron MX-20 digital radiography system. Cells 
where then slowly injected using a 27-G Kel-F hub needle on a Hamilton syring and 1min time 
was given for cells to accommodate in the medullary space before removing the needle. Post-
operative pain was managed by subcutaneous (s.c.) injection of Temgesic (60µg/kg). During the 
whole procedure, mice were placed on a feedback-controlled heating mat to maintain 
physiological body temperature. 
Behavioral Readouts of Spontaneous Pain Behavior   
Behavioral experiments were conducted in a blinded fashion every 5th day, starting 1 week 
after tumor inoculation (8, 13 and 18d.p.i.). Thereby, the animals were placed on a home-built 
mesh stand, enclosed in a 10x10x20cm compartment. Blinding was ensured by random placing 
of the animals in the absence of the experimenter conducting behavioral studies. All mice were 
habituated for 2x1h before start of the study. Before every experiment, mice were additionally 
habituated for 30min. Guarding and flinching behavior was analyzed over the period of 2min by 
video recording. Guarding was defined as holding the paw aloft while ambulatory, flinching was 
defined as holding the paw aloft while steady according to previously published procedures 
[6,29]. Number of guarding and flinching incidences was assessed from the video after the 
experiment.   
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Animal Preparation and Anesthesia 
For induction of anesthesia, mice were anesthetized using 4% isofluorane in a 1:5 mixture of 
O2/air for 4min before endotracheal intubation using PE-50/10 polyethylene tubing while 
maintaining anesthesia at 2%. Mice where cannulated intravenously (i.v.) in the lateral tail vein 
using a the tip of a 30-G needle, the animal was placed on the MRI-support before application of 
pancuronium bromide (0.05mg/kg, s.c.) and medetomidine hydrochloride (0.1mg/kg, i.v.) bolus. 
After 5min, isoluorane anesthesia was reduced to 0.5% and combined with a medetomidine 
hydrochloride infusion (0.05mg/kg/h, i.v.) during the course of acquisition. During experiments, 
mice were mechanically ventilated using a small animal ventilator at a rate of 80breaths/min with 
a cycle of 25% inhalation and 75% exhalation and 1.8ml inspiration volume. Functional data 
acquisition was consistently started 15min after the start of medetomidine infusion in order to 
ensure reproducible physiological states. In order to reduce motion artefacts, mouse heads were 
fixed using bite and ear bars. Body temperature was monitored using a rectal probe and 
maintained at 36.5±0.1°C during the course of the experiments. Upon termination of MRI 
experiments, animals were recovered on a heating map while still ventilated at 1% isofluorane 
until the effect of pancuronium bromide has worn off.  
Anti-NGF Treatment using Murine anti-NGF Monoclonal Antibody mAb911  
Murine monoclonal anti nerve growth factor (NGF) antibody mAb911 was kindly provided by 
Pfizer Inc. (Groton, CT, USA). Treatment regime and dosing were adopted from previous 
publications, demonstrating the effectiveness of mAb911 to reduce cancer-induced bone pain 
[47]. Anti-NGF treatment (10mg/kg, i.p.) was initiated prospectively at 8d.p.i. and repeated in 
intervals of 5days following behavioral experiments.  
MRI Acquisition Protocol 
Magnetic resonance imaging (MRI) experiments were conducted using a Biospec 94/30 small 
animal MR system with a 30cm horizontal bore operating at 400MHz (9.4T). For excitation and 
signal reception, a cryogenic quadrature transmit/receive surface coil was used. 
Resting-state fMRI: Functional data was acquired using a gradient-echo echo planar imaging 
(GE-EPI) sequence sensitive to the blood-oxygen level dependent (BOLD) contrast with the 
following parameters: Field of view (FOV) = 16x8mm2 and Matrix size (MTX) = 80x40, resulting in 
200x200µm2 in-plane resolution, 18 slices, slice thickness (SLTH) = 0.5mm, repetition time (TR) 
= 1000ms, echo time (TE) = 12ms, bandwidth (BW) = 200kHz and number of averages (NA) = 1. 
Acquisition time was 15min20sec (920 repetitions) of which the first 20 were discarded and 900 
were used for subsequent analysis. To prevent fold-over artefacts, one saturation slice was 
positioned at the base of the brain. 
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Data Processing and Statistical Analysis 
Functional scans were normalized to a MRI template (Australian Mouse Brain Mapping 
Consortium, http://www.imaging.org.au/AMBMC) using linear affine and non-linear greedy SyN 
transformation (ANTs V2.1, http://picsl.upenn.edu/software/ants/).  Independent functional 
components (ICs) were extracted on an individual level using MELODIC (Multivariate Exploratory 
Linear Optimized Decomposition of Independent Components [3]), taking the mean EPI image as 
a reference. This process included 0.01Hz high-pass filtering of the 4D dataset, spatial smoothing 
with a 2x2mm2 kernel and head motion correction using MCFLIRT [27]. Independent components 
were classified into physiological and non-physiological components using an in-house classifier 
[52], non-physiological components in the BOLD signal were regressed out using FIX (FMRIB’s 
ICA-based Xnoiseifier [20,44], v1.06). Classifier accuracy was tested using a subset of 10 
baseline scans, yielding an accuracy A (A=TNR+TPR/2) of 72.5%, TNR and TPR indicating true 
positive and true negative discovery rate, respectively, for the applied threshold during analysis. 
Group-level independent components of baseline scans were used as naïve animal reference 
resting state networks (RSN) to analyzed projection regions of seeds in the seed-based analysis 
approach.   
Region of interest (ROI) -based network analysis of whole brain connectivity was performed 
using a ROI-template comprising 75 anatomical ROIs based on the reference atlas of the Allen 
Institute for Brain Sciences (AIBS). Using fslmaths, average BOLD-timeseries were extracted 
from the normalized, filtered data. Pairwise Pearson’s correlation values were calculated between 
all ROI combinations to obtain subject and session specific correlation matrices. Fisher’s Z 
transformed correlation matrices were used in a linear mixed model analysis to test for group and 
session interaction effects (R, lme4 package). For the seed-based analysis, average timeseries 
were extracted from seeds and used in a general linear model (GLM) analysis (fsl_glm) as a 
regressor. Resulting subject and session level voxel-wise Z-score maps of seed projections were 
subsequently analyzed within target ROIs using previously described resting state networks as 
ROIs in a linear mixed model analysis, accounting for multiple comparisons (R, lme4, multcomp 
packages). 
Behavioral readouts of pain were analyzed using multiple t-tests (one per time-point), 
statistical significance was corrected for multiple comparisons using the Holm-Sidak method. 
Descriptive statistics are indicated as means ±1 standard deviation (SD) in all plots with a 
statistical significance level of P<0.05.  
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3. Results 
Behavioral Readouts of Spontaneous Pain 
A linear mixed model analysis indicated significant group and session interactions in the 
Tumor-Vehicle vs Control-Vehicle (P<0.0003 for guarding, P<0.0001 for flinching) and Tumor-
anti-NGF vs Control-Vehicle (P<0.04 for guarding and P<0.1 for flinching). Control-anti-NGF vs 
Control-Vehicle was not significant in both readouts. Post-hoc, we performed multiple t-tests, one 
per session, to determine statistically significant differences at each time point (Figure 2). 
Guarding behavior was found to be elevated in Tumor+Vehicle animals at 13 and 18d.p.i., while 
only a small increase in guarding was observed at 18d.p.i. in Tumor+anti-NGF mice. There was a 
significant treatment-effect visible between these two groups at 13 and 18d.p.i.. Sham operated 
animals did not show any significant guarding behavior irrespective of whether they were treated 
with vehicle or anti-NGF. Similar results have been obtained regarding flinching behavior, which 
was found to be elevated in Tumor+Vehicle animals at 18d.p.i. compared to any other group. In 
particular, Tumor+anti-NGF animals did not develop any significant flinching behavior resulting in 
a significant treatment-effect between for tumor mice at 18d.p.i.. Behavioral readouts of 
spontaneous pain behavior indicate development of pain in Tumor+Vehicle animals. This 
behavior could be largely prevented through prospective treatment using anti-NGF antibody 
mAb911 with only little residual guarding behavior displayed at 18d.p.i. in Tumor+anti-NGF 
animals.  
ROI-based Network analysis 
ROI-based analysis of longitudinal rs-fMRI data revealed distinct rearrangement of functional 
connectivity (FC) patterns in tumor-bearing as compared to sham-operated mice upon vehicle 
treatment (Figure 3, upper triangle). Interactions of amygdallar nuclei (Amg) with thalamic (Th) as 
well as midbrain (Mb) regions were found to be most significantly affected. A closer look on 
midbrain structures revealed FC changes to be mostly confined in motor-related areas and the 
periaqueductal gray. In addition, FCs to cortical areas (Ctx) were found to be affected; in 
particular interactions with temporal associative (TAc) / insular (IC) regions and the cingulate 
cortex (Cg). Furthermore, FC between the thalamus and cortical areas were specifically affected 
in somatosensory as well as temporal associative / insular regions (Supplementary Fig 1, 
available at http://links.lww.com/PAIN/A659). Less distinct but still significant changes were 
additionally observed between striatal (Str) and midbrain as well as thalamic regions.  
Prospective treatment of tumor-bearing mice using mAb911 successfully prevented previously 
observed effects of persistent pain on FC (Figure 3, lower triangle). Few remaining significant 
alterations were found in deep nuclei comprised in mid- and hindbrain (Hb) regions. The distinct 
patterns of altered connectivities associated with tumor development were virtually absent in 
Tumor+anti-NGF animals. 
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  Significant treatment effects of mAb911 are indicated in Supplementary Figure 2 (upper 
triangle), comparing animals of the Tumor+Vehicle and Tumor+anti-NGF groups (available at 
http://links.lww.com/PAIN/A659). FCs responding to treatment overlapped to a large extent with 
FCs exhibiting significant changes due to tumor development (Fig. 3; upper triangle). In order to 
exclude intrinsic effects of mAb911 treatment we compared FC in Sham+Vehicle and Sham+anti-
NGF mice (Supplementary Figure 2, lower triangle, available at  http://links.lww.com/PAIN/A659). 
We did not find significant differences between the groups except minor effects on FC between 
midbrain and striatal and amygdallar regions indicating low significance and random distribution 
across the brain.    
In summary, we found distinct patterns on FC alterations within main regions of ascending and 
descending pain pathways in the untreated tumor-bearing group. These FC rearrangements 
could be largely prevented following prospective mAb911 treatment and significant treatment 
effects were found. Intrinsic effects of mAb911 treatment on brain functional networks appear to 
be largely absent, a least for the treatment regime applied.  
Seed-based analysis 
For analyzing effects of cancer-induced bone pain on FC and their modulation by anti-NGF 
treatment, a seed-based analysis was carried out using the main nuclei of ascending and 
descending nociceptive pathways as seed regions. The regions were chosen according to 
previously described results of ROI-based network analysis (Figure 3) in both hemispheres 
separately, in nuclei of the amygdala, anterior and posterior part of the periaqueductal gray, 
thalamus and the motor-related portion of the superior colliculus. Alterations of regional seed FC 
was analyzed within bilateral target reference resting state networks derived from naïve animals 
using independent component analysis [52]. Statistical significance was assessed using a linear 
mixed model analysis testing for significant group and session interaction, corrected for multiple 
comparisons was conducted using false discovery rate (FDR) correction.    
Significant effects were found for FC between the amygdallar seed (lAmg) contralateral to the 
tumor site and thalamic (Th, p=0.004), dorsal hippocampal (dHp, p=0.006) and somatosensory 
(B1c, p=0.021) areas (Figure 4). Furthermore, FC between the anterior periaqueductal gray seed 
(aPAG) and barrelfield 2 cortex (B2c, p=0.032), posterior periaqueductal gray seed (pPAG) and 
limb cortex (Lc, p=0.032) as well as ipsilateral motor related superior collicular seed (rSCm) seed 
and the amygdala (Amg, p=0.035) were found to be significantly affected in the Tumor+Vehicle 
group. These changes in FC could be prevented by treatment with anti-NGF antibodies as the 
Tumor+anti-NGF group did not display altered FCs in these regions when compared to 
Sham+Vehicle animals. FC of the contralateral amygdallar seed to the cingulate cortex indicated 
the same trend, though the effect did not reach statistical significance (p=0.136, data not shown). 
As a control, FC was analyzed using a seed in the ipsilateral amygdala (rAmg), a region that does 
not receive direct nociceptive input. FC from the right amygdala to the thalamus, barrelfield 1 
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cortex and dorsal hippocampus, the corresponding regions to those displaying altered FC to the 
left amygdala, was not affected by the developing tumor in the right leg (Th p=0.334, B1c p=0.479 
and dHp p=0.307, Supplementary Figure 3, available at http://links.lww.com/PAIN/A659) as Z-
scores in respective regions were found to be stable in all groups and measurement sessions. 
Assessment of treatment effects at 20d.p.i revealed that mAb911 administration prevented FC 
changes between the left amygdallar seed and the dorsal hippocampus (p=0.031) and barrelfield 
1 cortex (p=0.013). Furthermore, FC between the anterior periaqueductal gray seed and the 
barrelfield 2 cortex (p=0.004) as well as between the posterior periaqueductal gray seed and the 
limb cortex (p=0.012) were significantly modulated by the treatment. Significant FC changes upon 
a persistent pain from bone cancer which could be prevented through mAb911 administration are 
schematically visualized in Figure 5. Affected connectivities are depicted with respective 
differences in Z-scores (∆Z) comparing Tumor+Vehicle vs Sham+Vehicle animals, indicating 
effect-sizes of FC differences induced by bone cancer pain which could be prevented through 
mAb911 administration.   
For visualizing treatment effects of mAb911, FC at 20d.p.i. was compared in animals of the 
Tumor+Vehicle and Tumor+anti-NGF groups versus the Sham+Vehicle group using an unpaired 
t-tests on a voxel by voxel basis (fsl-randomise). Uncorrected t-statistical maps visualized 
previously described effects indicate voxels within a reference resting state network, where seed 
FC is increasing (>) compared to Sham+Vehicle controls (Figure 6). While Tumor+Vehicle 
animals consistently indicate reduced FC between seeds and reference resting state networks 
compared to Sham+Vehicle animals, this reduction in FC could be significantly prevented in the 
Tumor+anti-NGF group.  
 
4. Discussion 
Using longitudinal rs-fMRI and behavioral readouts of spontaneous pain in a mouse model of 
cancer pain from bone metastasis we assessed efficacy of the NGF sequestering antibody 
mAb911 to prevent cancer-induced bone pain. The primary molecular target of NGF is TrkA, to 
which it binds with a high affinity, leading to the formation of homodimers [10]. More recent 
findings suggest NGF binding to p75NTR, forming a heterodimer which is presented to TrkA [1]. 
Formation of such homo- and heterodimers leads to activation of secondary-messenger 
cascades, modulating expression patterns of receptors and ion channels on peripheral nerve 
endings and induce sensitization through a variety of neurotransmitters [35]. Additionally, NGF 
induces sprouting and hyper-innervation of bones in metastatic bone diseases leading to the 
development of skeletal pain [33]. While there is some knowledge on pathways affected by NGF, 
the exact molecular mechanisms and cell-type specific expression patterns are still not clear. 
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  The effects of NGF on peripheral nociceptors indicates fast sensitization of neurons towards 
chemical, mechanical and thermal stimuli, which translate into prolonged alterations fibers 
affecting CNS function [2]. Anti-NGF treatment has been shown to prevent such effects, as typical 
neurochemical changes in the spinal cord as a result of cancer induced bone pain could be 
prevented [47].  Furthermore, anti-NGF treatment has been shown to be effective in a rat model 
of spinal cord injury, in which anti-NGF antibodies successfully suppressed mechanical 
hyperalgesia and increased responsiveness of wide dynamic range neurons in the spinal cord 
[21]. Nevertheless, studies indicating direct effects of NGF and anti-NGF treatment on the CNS 
remain sparse, probably due to the fact that target receptor expression is largely limited to 
peripheral nociceptors both in mammals and rodents [36,49]. Moreover, direct effects are 
expected to be minimal due to poor CNS penetration of IgG molecules (>0.1% [39]), whereas 
circulating concentrations are much higher. Therefore, effects of anti-NGF treatment in the CNS 
arise most likely from altered peripheral nociceptive processing rather than direct central action.  
Along the lines of these results, our findings indicate efficacy of anti-NGF treatment to prevent 
FC in the brain following cancer-induced bone pain. We have shown alterations in in major hubs 
of ascending and descending pain pathways [14,34]. In particular, we found profound alterations 
affecting connections form the contralateral amygdallar nuclei to cortical somatosensory (B1c, 
B2c, Lc) and limbic structures such as cingulate, temporal associative and insular cortex as well 
as the midbrain. Midbrain structures indicated altered connectivities mostly in motor-related 
areas, likely reflecting impaired motor function of the tumor-bearing limb. Seed-based analysis 
supported these findings and furthermore indicated altered connectivities between the anterior 
and posterior periaqueductal gray and cortical structures, which are directly linked through the 
ascending spinothalamic tract. Connectivities involving thalamic regions were found less affected. 
This could be attributed to the anesthesia regime comprising medetomidine, which is known to 
disrupt thalamo-cortical connectivity in fMRI experiments [15,19,38]. The regions mentioned 
above play important roles in nociceptive transmission and encoding of painful stimuli. As they 
were found to be unaffected upon prospective treatment with anti-NGF treatment, our study 
indicates the efficacy of such treatments for preventing FC alterations elicited by persistent pain. 
While hemispheric lateralization of the amygdala in emotional processing is well documented, its 
role in pain processing is still not fully understood. As pain comprises a strong emotional and 
affective component, the amygdala plays a critical role in modulating such components as well as 
in direct modulation of pain perception [8]. Neurons of the latero-capsular division of the central 
nucleus of the amygdala (CeLC) have been described to receive specific nociceptive inputs from 
different body regions in rats. The right amygdala receives input from deep tissue, both hindlimbs 
as well as the tail while left amygdala CeLC neurons respond mostly to nociceptive input in the 
contralateral hindlimb. Nevertheless, electrophysiological studies have found unique activation of 
the right amygdallar CeLC in response to induction of knee arthritis [28].  On the other hand, a 
transient increase in left amygdallar activity has been described in a neuropathic pain condition in 
vivo using electrophysiological recordings while at late stages of the model the right amygdala 
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was activated predominantly [17]. The discrepancy between those results and our study might 
arise from the nature of pain derived from bone metastasis which comprises several aspects such 
as nociceptive, neuropathic and inflammatory pain rather than being purely neuropathic. 
Additionally, processing of emotional components by amygdallar CeLC neurons has been 
described to occur predominantly on the right in male subjects, while in female subjects these 
processes occurred predominantly in the left amygdala [7]. More recent studies have also 
suggested that the right amygdala is predominantly involved in pro-nociceptive signaling, while 
the left amygdala processes anti-nociceptive signals [43]. Therefore, our findings might indicate a 
failing top-down suppression of nociceptive signaling at the last fMRI time point which has been 
described to be mediated by the infralimbic medial prefrontal cortex [41].     
Cancer pain associated FC alterations could be successfully prevented through the 
prospective administration of anti-NGF antibody mAb911 with only few residual interactions. 
Seed-based analysis indicated no changes in connectivity strength as indicated by Z-scores as a 
function of time in Tumor+anti-NGF mice throughout the observation period. In fact, values were 
not different from those measured in Sham+Vehicle animals at all time points. This indicates on 
one hand the specificity of FC alterations for tumor-associated persistent pain, and on the other 
hand the effectiveness of mAb911 treatment in preventing these pathological changes. 
Additionally, control-seeds in the ipsilateral amygdallar nucleus did not show previously observed 
trends, endorsing the validity of obtained results and further underlining their specificity 
(Supplementary Figure 1, available at http://links.lww.com/PAIN/A659). Residual alterations, as 
observed in the ROI-based network analysis, were to be expected as behavioral readouts of pain 
(guarding) indicated weak but significant spontaneous pain behavior at 20d.p.i. in the 
Tumor+anti-NGF group. These effects are unlikely due to direct central effect of anti-NGF 
treatment as the comparison of Sham+Vehicle and Sham+anti-NGF mice displayed only minimal 
differences in FC patterns affecting Mb regions but not pain associated ascending and 
descending pathways. This is in line with reports stating that NGF target receptors are largely 
absent from the CNS except from basal forebrain cholinergic neurons, where low levels of TrkA 
expression was described [45]. The absence of central NGF receptors together with the low CNS 
penetration of IgG molecules suggest minimal non-specific effects on FC While anti-NGF 
treatment addresses important aspects of bone cancer pain such as neuropathic and 
inflammatory nociceptive processes, additional processes not related to NGF such as bone 
remodeling associated with tumor growth will trigger peripheral mechanical pain stimuli, which 
might lead to residual FC changes described.  
Regarding behavioral readouts, we would like to mention that the difference between tumor-
bearing and sham-operated animals regarding the number of flinches and the time spent 
guarding reported in this study appears low in absolute numbers. This can be attributed to the 
early time points of measurements (day 13 and 18 following tumor implantation), which have 
been chosen to investigated early changes in the brain functional architecture in response to 
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nociceptive input.  In fact, the behavioral measures of the current study follow the trajectory of 
developing behavioral signs of pain that has been reported previously for this model [6], 
illustrating good reproducibility. Considering the effect size of behavioral symptoms between 
tumor-bearing and sham-operated animals, our results are in line with results obtained from a 
similar tibial bone cancer model, though using a different tumor cell line and mouse strain [29]. 
Differences in absolute values are not surprising as it has been reported that the extent of 
behavioral signs of pain depends on the mouse strain used [37] and almost certainly also on the 
osteolytic potential of the tumor cells. Therefore, comparisons of absolute numbers in behavioral 
readouts of nociception should be viewed with care.    
Prospective treatment using mAb911 effectively prevented FC alterations observed in tumor-
bearing untreated animals. It has been previously shown that anti-NGF treatment effectively 
reverses nerve sprouting, neuroma formation and nociceptive behavior upon preventive 
administration as well as under a therapeutic treatment regime in mice [29]. While preventive 
administration is certainly more effective as it blocks pathological nociceptor alterations before 
they occur, it typically does not represent the clinical situation. Nevertheless would preventive 
administration most likely be desirable also in a clinical setting in order to effectively prevent such 
pathological events, thereby counteracting development of a pain state from bone metastasis in 
affected patients. Thereby, efficacy of anti-NGF antibody mAb911 to reverse FC alterations after 
their development could be assessed in future studies.  
In summary we could show that anti-NGF treatment using mAb911 not only effectively 
prevents peripheral nociceptive processes but also effects on FC of the brain, as indicated by rs-
fMRI. This supports previously published promising effects of anti-NGF antibody mAb911 to 
effectively prevent and treat cancer-induced skeletal pain.      
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Figure Captions 
Figure 1 | Experimental design. Resting-state fMRI experiments were carried out -2, 10 and 20d.p.i.. At 0d.p.i., 
mice of the tumor groups were injected with EO771 breast cancer cells (T) control mice with PBS (C). Guarding 
and flinching (G/F) behavior was assessed on the same days as application of treatment was performed, 
treatment-groups receiving anti-NGF mAb911 (10mg/kg, i.p.) while vehicle groups received physiological saline 
instead.  
Figure 2 | Behavioral readouts of spontaneous pain behavior. Guarding and flinching was assessed during a 
period of 2min. Statistical significance was tested post-hoc per timepoint compared to Sham+Vehicle using t-tests 
accounting for multiple comparisons (Holm-Sidak method). Brackets indicate significant treatment-effects, 
comparing Tumor+anti-NGF to Tumor+Vehicle (* p<0.05, ** p<0.01 and *** p<0.001)  
Figure 3 | ROI-based network analysis of longitudinal rs-fMRI readouts. Pair-wise correlations between different 
ROIs were calculated for all sessions. Alterations in persistent pain and effects of treatment were tested for 
statistical significance using a linear mixed model analysis, testing for significant longitudinal group and session 
interaction. Respective p-values are plotted in a heatmap. The upper triangle indicates significant differences 
between Tumor+Vehicle and Sham+Vehicle animals. The lower triangle represents the comparison between 
Tumor+anti-NGF and Sham+Vehicle animals, i.e. the effect of the treatment on FC, indicating only little 
differences between the two groups.  
Figure 4 | Seed based correlations were analyzed in regions of interest, plotting Z-scores as group averages. 
Projections of the left amygdallar seed (L Amg) to the thalamus (Th), dorsal hippocampus (dHp) and the 
barrelfield 1 cortex (B1c) indicate FC changes in Tumor+Vehicle animals, while other groups were not altered. 
Furthermore, projections of the right superior colliculus seed (R SCm) to the amygdalar RNS, anterior 
periaqueductal gray (aPAG) seed to the barrelfield 2 cortex (B2c) RNS and posterior peraqueductal gray (pPAG) 
seed to the limb cortex RSN were found to be altered in Tumor+Vehicle animals only.  Statistical significance was 
assessed in a linear mixed model testing for group and session interaction as well as for a group effect in session 
3 in order to assess a significant treatment effect (* p<0.05, ** p<0.01).  
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Figure 5 | Visualization of FCs derived from seed-based analysis that exhibited significant difference when 
comparing sham-operated mice with animals displaying persistent pain from bone cancer as revealed by 
behavioral tests. All these FC changes could be successfully prevented by treatment with the monoclonal 
antibody mAb911. Individual seeds used to extract z-scores are color coded as are the FCs originating from the 
respective seed. Effect-size of functional alterations are indicated as differences in Z-scores (∆Z) comparing 
Tumor+Vehicle vs Sham+Vehicle animals. No directionality can be inferred from the correlation analysis. P-values 
for the individual FCs are given in text. 
Figure 6 | FC differences in affected resting-state networks as deduced by seed-based analysis at 20d.p.i.. 
Uncorrected t-statistical maps visualizing increasing seed FC within RSN in Tumor+Vehicle compared to 
Sham+Vehicle animals are indicated in the left column, while Tumor+anti-NGF compared to Sham+Vehicle 
animals are depicted in the right column.  Efficacy of mAb911 treatment to prevent FC alterations is indicated 
through a reduction of altered FC in the Tumor+anti-NGF compared to the Tumor+Vehicle group.  Significance of 
differences between groups are indicated in a heatmap representing t-statistics on a voxel-wise basis.  
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Experimental Group Surgical Procedure Treatment Group-Size 
Sham+anti-NGF 10µl PBS, intramedullary mAb911, 10mg/kg, i.p. N=7 
Sham+Vehicle 10µl PBS, intramedullary 50µl Saline N=7 
Tumor+anti-NGF 105 EO771, intramedullary mAb911, 10mg/kg, i.p. N=8 
Tumor+Vehicle 105 EO771, intramedullary 50µl Saline N=8 
Table 1 | Experimental groups as referred in the text. All surgical procedures were performed on the right 
tibia. mAb911 was diluted in 50µl physiological saline before injection. 
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